![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PJA1 |
Gene summary for PJA1 |
![]() |
Gene information | Species | Human | Gene symbol | PJA1 | Gene ID | 64219 |
Gene name | praja ring finger ubiquitin ligase 1 | |
Gene Alias | PRAJA1 | |
Cytomap | Xq13.1 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q8NG27 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
64219 | PJA1 | P128T-E | Human | Esophagus | ESCC | 1.03e-12 | 4.25e-01 | 0.1241 |
64219 | PJA1 | P130T-E | Human | Esophagus | ESCC | 3.16e-21 | 4.97e-01 | 0.1676 |
64219 | PJA1 | C04 | Human | Oral cavity | OSCC | 4.99e-05 | 3.46e-01 | 0.2633 |
64219 | PJA1 | C21 | Human | Oral cavity | OSCC | 1.96e-22 | 6.26e-01 | 0.2678 |
64219 | PJA1 | C30 | Human | Oral cavity | OSCC | 4.49e-27 | 8.70e-01 | 0.3055 |
64219 | PJA1 | C43 | Human | Oral cavity | OSCC | 6.58e-25 | 4.99e-01 | 0.1704 |
64219 | PJA1 | C46 | Human | Oral cavity | OSCC | 7.57e-19 | 3.71e-01 | 0.1673 |
64219 | PJA1 | C51 | Human | Oral cavity | OSCC | 1.20e-03 | 3.17e-01 | 0.2674 |
64219 | PJA1 | C57 | Human | Oral cavity | OSCC | 2.13e-02 | 1.64e-01 | 0.1679 |
64219 | PJA1 | C06 | Human | Oral cavity | OSCC | 1.53e-07 | 1.03e+00 | 0.2699 |
64219 | PJA1 | C08 | Human | Oral cavity | OSCC | 1.19e-15 | 3.91e-01 | 0.1919 |
64219 | PJA1 | C09 | Human | Oral cavity | OSCC | 6.87e-04 | 1.68e-01 | 0.1431 |
64219 | PJA1 | LN46 | Human | Oral cavity | OSCC | 9.52e-06 | 3.04e-01 | 0.1666 |
64219 | PJA1 | SYSMH2 | Human | Oral cavity | OSCC | 3.00e-05 | 2.17e-01 | 0.2326 |
64219 | PJA1 | SYSMH3 | Human | Oral cavity | OSCC | 6.33e-07 | 2.34e-01 | 0.2442 |
64219 | PJA1 | SYSMH5 | Human | Oral cavity | OSCC | 6.70e-03 | 1.99e-01 | 0.0647 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PJA1 | SNV | Missense_Mutation | rs763045220 | c.25G>T | p.Val9Leu | p.V9L | Q8NG27 | protein_coding | deleterious(0.05) | benign(0) | TCGA-A1-A0SK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
PJA1 | SNV | Missense_Mutation | c.171N>A | p.His57Gln | p.H57Q | Q8NG27 | protein_coding | tolerated(0.29) | possibly_damaging(0.446) | TCGA-A2-A04T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
PJA1 | SNV | Missense_Mutation | novel | c.1129C>T | p.Arg377Trp | p.R377W | Q8NG27 | protein_coding | tolerated(0.2) | possibly_damaging(0.451) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PJA1 | SNV | Missense_Mutation | c.1613N>C | p.Met538Thr | p.M538T | Q8NG27 | protein_coding | deleterious(0) | possibly_damaging(0.838) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PJA1 | SNV | Missense_Mutation | novel | c.1354N>C | p.Glu452Gln | p.E452Q | Q8NG27 | protein_coding | tolerated(0.05) | benign(0.259) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PJA1 | SNV | Missense_Mutation | c.280G>A | p.Glu94Lys | p.E94K | Q8NG27 | protein_coding | tolerated(0.12) | benign(0.411) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
PJA1 | SNV | Missense_Mutation | c.254N>T | p.Ser85Leu | p.S85L | Q8NG27 | protein_coding | tolerated(0.55) | probably_damaging(0.978) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PJA1 | SNV | Missense_Mutation | c.581N>A | p.Arg194Lys | p.R194K | Q8NG27 | protein_coding | tolerated(0.3) | benign(0.003) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PJA1 | SNV | Missense_Mutation | novel | c.1689G>T | p.Glu563Asp | p.E563D | Q8NG27 | protein_coding | deleterious(0.04) | probably_damaging(0.956) | TCGA-LL-A7SZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
PJA1 | SNV | Missense_Mutation | novel | c.472N>A | p.Ala158Thr | p.A158T | Q8NG27 | protein_coding | tolerated(0.14) | benign(0.055) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |